Холитилин®

General characteristics. Structure:

Active agent: Sincaline of an alfostserat polyhydrate (Lipoid GFKH 85f), in terms of sincaline альфосцерат 1000 mg;

excipients: povidone, water for injections.

Description: the transparent colourless or slightly painted liquid.

Pharmacological properties:

Pharmacodynamics. Nootropic means. The central holinostimulyator as a part of which 40,5% of metabolic protected sincaline contain.

Provides synthesis of acetylcholine and phosphatidylsincaline in neyronalny membranes, improves a blood stream and strengthens metabolic processes in TsNS, activates a reticular formation. Increases the linear speed of a blood-groove, contributes to normalization of spatio-temporal characteristics of spontaneous bioelectric activity of a brain, regress of focal neurologic symptoms and recovery of consciousness; exerts positive impact on cognitive and behavioural reactions of patients with vascular diseases of a brain (distsirkulyatorny encephalopathy and the residual phenomena of disturbance of cerebral circulation).

Has preventive and corrective effect on pathogenetic factors of an involutional psychoorganic syndrome, reduces cholinergic activity. Stimulates dozozavisimy allocation of acetylcholine in physiological conditions; participating in phosphatidylsincaline synthesis (membrane phospholipid), improves synoptic transfer, plasticity of neyronalny membranes. Does not exert impact on a reproductive cycle and does not possess teratogenic, mutagen action.

Pharmacokinetics. Sincaline альфосцерат easily gets through a blood-brain barrier. It is removed preferential easy in the form of carbon dioxide (85%), and also kidneys and through intestines (15%).

Indications to use:

In complex therapy at:

- to a craniocereberal injury with preferential trunk level of defeat (the acute period);

- cerebrovascular insufficiency;

- a psychoorganic syndrome against the background of degenerative diseases and involutional processes of a brain;

- multiinfarctive dementia.

Route of administration and doses:

The drug is administered intramusculary in a dose of 1 g (1 ampoule) in days or intravenously slowly on 1 g a day within 15–20 days.

Further transition to a peroral form of drug (capsule) is possible.

Features of use:

During treatment it is necessary to be careful during the driving of motor transport and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Side effects:

From the alimentary system: lock, diarrhea, dryness of a mucous membrane of an oral cavity, pharyngitis.

From a nervous system: headache, drowsiness, sleeplessness, aggression, alarm, nervousness, dizziness.

From integuments: rash, urticaria.

Others: pain in an injection site, increase of an urination.

Interaction with other medicines:

Medicinal interaction of drug is not established.

Contraindications:

- hypersensitivity;

- hemorrhagic stroke (acute stage);

- pregnancy;

- breastfeeding period;

- age up to 18 years.

Storage conditions:

List B. In the dry, protected from light place at a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity 2 years. Not to apply after a period of validity.

Issue conditions:

According to the recipe

Packaging:

Solution for intravenous and intramuscular administration of 250 mg/ml.

On 4 ml in the ampoules from colourless glass of the 1st hydrolytic class having a break point.

On 3, 5 or 10 ampoules place in a blister strip packaging from a film polyvinyl chloride.

On 1 or 2 blister strip packagings together with the application instruction place in a pack from a cardboard.

It is allowed to put the scarificator in a pack.